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Abstract
Background: Premature thelarche (PT) seems to be increasing and it is difficult to differentiate its early stages from
precocious puberty (PP). Clinical and biochemical parameters are warranted to differentiate the two diagnoses.
Methods: One hundred ninety-one girls aged 0.5–7 years were included. Diagnoses were validated and the girls
were categorized to the groups PP (n = 27) and PT (n = 164). Anthropometry, Tanner stages, ethnicity, bone age,
and biochemistry, were recorded. Conventional variables for diagnosing PP were compared between the groups
at time of referral to identify parameters predictive for the diagnosis.
Results: The referral rate of PT increased from 1998–2013. Girls with PT and PP differed with regards to age at
referral, body mass index standard deviation scores (BMISDS), ethnicity, bone age advancement, basal luteinizing
hormone (LH), gonadotropin releasing hormone (GnRH) stimulated LH and follicle stimulating hormone (FSH), basal
and stimulated LH/FSH ratio, and sex-hormone binding globulin (SHBG). Apart from SHBG there was considerable
overlap of the variables between the PT and the PP groups.
Conclusions: First, the incidence of PT appears to increase. Second, SHBG was the variable which best discriminated PT
from PP. Third, stimulated LH in 1–3 years old girls with PT is similar to stimulated LH in 5–7 years old girls with PP. Age,
BMISDS, ethnicity, bone age, stimulated gonadotropins and LH/FSH and SHBG are all useful variables for differentiating
PP from PT. However normative data for stimulated LH and FSH in the age group 0.5–7 years are warranted.
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Background
Onset of puberty before eight years of age for girls, so-
called precocious puberty (PP), is increasing [1–3]. PP is
associated with reduced adult height [4], psychosocial
problems [5, 6], and may be associated with breast can-
cer [7] and the metabolic syndrome [8]. The first clinical
sign of puberty in girls is usually breast development
(thelarche). Thelarche is accompanied with accelerated
growth velocity and bone age advancement. Early stages
of PP in girls are, therefore, difficult to differentiate from
premature thelarche (PT), which is defined as isolated
breast development before eight years of age [9].
The frequency of PT seems dependent on ethnicity
and may be increasing [10]. In an U.S. study the inci-
dence rate of PT in the period 1940–1984 was 2.1 per
10,000 person years [11]. PT is a self-limiting condition
in the majority of girls, but it may progress into PP in a
* Correspondence: mies@clin.au.dk
†Equal contributors
1Department of Pediatrics, Aarhus University Hospital, Skejby, Palle Juul
Jensens Boulevard 99, DK-8200 Aarhus N, Denmark
Full list of author information is available at the end of the article
© 2016 Sømod et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sømod et al. International Journal of Pediatric Endocrinology  (2016) 2016:4 
DOI 10.1186/s13633-016-0022-x
subset of girls [12–14]. De Vries et al. and Pasquino et
al. reported that 13 % and 14 %, respectively, of girls
with PT progressed into PP [13, 14]. It is of great im-
portance to identify the girls with PT, who progress into
PP [9], and to initiate medical treatment to circumvent
the negative implications of PP [15].
Unfortunately, robust clinical, biochemical and im-
aging indicators to help clinicians differentiate PT from
PP are lacking, and no single test can predict the pro-
gression from PT to PP [12–14]. Diagnostic tests that
may help to differentiate PT from PP include pelvic ultra-
sound measurements [16], bone age evaluation, basal
luteinizing hormone (LH), and gonadotropin releasing
hormone (GnRH) test, although normative data for the
GnRH test in the first years of life have not yet been
established.
The aim of this study was to test the hypothesis that
the incidence of PT in girls in the Central Region of
Denmark is increasing. A further aim was to describe
challenges in differentiating girls with PT from girls with
early PP using conventional variables for diagnosing PP
in real-life practice.
Methods
We identified girls aged 0.5–7 years referred for breast de-
velopment between January 1998 and September 2013 to
the pediatric departments in the Central Region of
Denmark (population 1,277,538).
For screening purposes, all patient files of girls who were
registered in the Danish National Patient Registry with the
ICD10 codes as listed in Table 1, were carefully reviewed.
The girls were included in the study, if they presented
with uni- or bilateral breast development corresponding
to Tanner stage 2 or more. Ninety-four girls did not meet
the inclusion criteria and were subsequently excluded
from further analysis. Girls were excluded because 1) they
did not have breast development at the first visit (either
because of regression or misdiagnosis or they had isolated
adrenarche) and 2) data on breast development were
missing in the patient file. Girls were assigned to the PP
group if they, at the time of referral or before their seventh
year, were diagnosed with PP by a pediatric endocrinologist.
For validating girls into the PP group they were required to
meet the following criteria: breast Tanner stage 2 or more
combined with one or more of the following: pubic hair,
accelerated growth velocity and bone age greater than 2 SD
above the chronological age. Further, they should have a
pubertal response (primarily assessed by the peak LH/FSH
ratio and the LH response > 5 IU/L ) if they underwent a
GnRH test at time of referral and data were available. For
validating girls into the PT group they were required to
have breast development corresponding to Tanner stage 2
or more, without any other signs of puberty.
The following parameters were extracted from the pa-
tient charts: Ethnicity, anthropometry, Tanner stages of
breast and pubic hair, bone age [17], magnetic resonance
imaging of the brain (MRI) and biochemistry: Estradiol,
inhibin B, sex hormone-binding globulin (SHBG), thyroid
stimulating hormone (TSH) luteinizing hormone (LH),
follicle stimulating hormone (FSH), and the FSH and LH
concentrations 30 min after an intravenous injection of
0.1 mg/m2 Relefact® (a GnRH agonist), hereafter desig-
nated stimulated LH and FSH concentrations.
Some turned 7 years before a GnRH test was performed.
The presented biochemical data represent the results from
the first blood samples after referral.
The number of newborn girls per year and girls in the
age group 0–7 years in the Central Region of Denmark
from 1998 to 2013, were obtained from ‘Statistics
Denmark.’
The study was approved by the National Research Ethics
Committee (reference number 1-10-72-186-13) and the
Danish Data Protection Agency (reference number 1-16-
02-118-13).
Assays
Up to March 2008 LH, FSH, estradiol and TSH levels were
measured by chemilu-minescence immunoassay (Siemens
Bayer Advia Centaur CP Immunoassay). Since March 2008
LH, FSH, estradiol and TSH were measured by electro-
chemiluminescence immunoassay (Roche Cobas E 601,
module immunology analyzer). SHBG levels were mea-
sured by chemiluminescence immunoassay (Siemens
Bayer Advia Centaur CP Immunoassay) up to November
2010 and since then by electrochemiluminescence im-
munoassay (Roche Cobas E 601, module immunology
analyzer). Serum levels of Inhibin B were measured by the
Beckman Coulter GenII assay.
Table 1 ICD10-diagnosis codes used for the registry extraction
ICD10-code Description
N60.X Disorders of breast
N62.X Hypertrophy of breast
N63.X Unspecified lump in breast
N64.9 Disorder of breast, unspecified
E30.X Disorders of puberty, not elsewhere classified
Q78.1 McCune Albright
E22.8 Central precocious puberty
E25.0 Congenital adrenal hyperplasia
E270B Premature adrenarche
E25.X Pseudopuberty
Codes where a diagnosis of premature thelarche or precocious puberty could
potentially have been misclassified were included
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Statistics
Statistical analysis was performed by SPSS software ver-
sion 21. Linear distributed data are presented as mean
and SD, while nonlinear distributed data are presented
as median and range. Body mass index standard deviation
score (BMI SDS) was calculated according to Nysom et al.
[18]. An independent samples T test was used to compare
the means of the parametric variables in the two groups
(PP vs. PT). Some parameters were ln-transformed to ob-
tain normal distribution. Non-parametric variables were
compared using Mann-Whitney U test. Binary variables
were analyzed using chi-square test. A difference was con-
sidered statistically significant at p < 0.05.
Results
In total 285 patients were identified. Ninety-four patients
did not meet the inclusion criteria and the remaining 191
girls (0.5 to 6.9 years) were included in the study
and allocated to the PP group (n = 27) or the PT
group (n = 164). One girl with PP was diagnosed with
central PP (hamartoma of tuber cinereum), and the
rest were diagnosed with idiopathic central PP. None
of the girls was diagnosed with peripheral PP.
Incidence
The annual incidence ranged from 0 to 1 and from 1 to
4 per 10,000 girls for PP and PT, respectively, (Fig. 1).
Non-biochemical characteristics
Girls with PP were older at referral (p < 0.001) (Table 2):
14.8 % (n = 4) were in the age group 0.5–2 years,
whereas 77.7 % (n = 21) were 5–7 years old. For girls
with PT the majority (70.7 %, n = 116) was referred at
age 0.5–2 years, Fig. 2.
A greater percentage of girls with PP were of non-
European origin (p = 0.012) and presented with a higher
BMI SDS (p < 0.001) compared to the girls with PT.
85.2 % of the girls with PP and 38.4 % of the girls with
PT had a bone age examination. Bone age was advanced
in all of the PP girls with a median advance of 23 months
and in the PT girls bone age deviated from chronological
age with a median of plus 4 months (p < 0.001).
Biochemical characteristics
SHBG levels were decreased in the PP group (p = 0.007),
and there was no overlap between the PT and the PP
group (Table 2). No between-group differences were ob-
served for estradiol, inhibin B, and TSH (Table 2).
Nineteen girls (70.4 %) with PP, median age 6.0 years,
and 47 girls (28.7 %) with PT, median age 2.3 years,
underwent a GnRH test. Basal LH and stimulated values
were significantly increased in the PP group compared
with the PT group (p = 0.016 and p < 0.001, respectively),
whereas the stimulated FSH value was decreased in the PP
group compared with the PT group (p = 0.001) (Table 2). A
stimulated LH-response ≥5 IU/l was recorded in 57.9 % of
the girls with PP and in 38.3 % of the girls with PT.
Stimulated LH/FSH ratio was 0.7 (0.3; 2.7) for the PP-
group and 0.2 (0.05; 1.3) for the PT-group (p < 0.001),
Table 2. The LH/FSH ratio was ≥1 for 8 (42.1 %) of the PP
girls and 1 (2.1 %) of PT girls (due to a low stimulated
FSH value). The basal LH/FSH ratio also indicated a sig-
nificant difference between the groups (p = 0.03), Table 2.
The stimulated LH and FSH concentrations are presented
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Fig. 1 Incidence of precocious puberty and premature thelarche expressed as an incidence rate and defined as:
No: of girls who got a diagnosis of PP or PT in a certain year
Total no: of girls 1=2−7 years living in the region
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in Figs. 3 and 4, respectively. The youngest girls exhibited
the largest stimulated FSH responses. Some girls with PT
in the age group ½-3 years had a stimulated LH response
comparable to the stimulated LH response in girls pre-
senting PP 5–7 years old. The stimulated LH/FSH ratios
was less than 0.6 in 46 of 47 girls with PT and higher than
0.6 in 11 of 19 girls with PP, Fig. 5.
Discussion
Breast development before the age of 7 years of age is
often an isolated and self-limiting condition. It can,
however, also be the first sign of precocious puberty,
which needs further examinations and medical treat-
ment to prevent psychosocial, metabolic, and cardiovas-
cular adverse events. While it is well known that the
incidence of premature thelarche was increasing in the
period from 1940 to 1984 [11] and that the timing of
pubarche is still declining [3, 19, 20] it remains to be in-
vestigated, if the incidence of premature thelarche has
continued to increase. We addressed this question and
the novel finding of our study is that the incidence of
girls referred because of premature thelarche before the
Table 2 Clinical and biochemical data of girls with precocious puberty (PP) and premature thelarche (PT)
Variable PP n= PT n= P-value
Age at referral (years)a 5.9 (1.0-6.9) 27 1.3 (0.5-6.9) 164 0.000
European origin (%) 70.4 27 89.6 164 0.012
BMI SDS +0.8 (0.3-1.3) 27 -0.3 (-0.5-(-) 0.1) 132 0.000
Bone age advancement (months)b 23.0 (3.0-48.0) 23 4.0 (1.0-19.0) 64 0.000
Estradiol (pg/mL)a 30.0 (18.0-137.0) 13 18.4 (13.0-85.0) 77 0.288
Inhibin B (pg/mL) 44.2 (23.9-64.4) 12 30.2 (25.6-34.7) 50 0.165
TSH (IU/L) 2.6 (2.1-3.1) 17 2.5 (2.2-2.8) 73 0.827
SHBG (nmol/L) 81.1 (60.2-101.9) 12 114.5 (102.3-126.8) 37 0.007
LH0 (IU/L)b 0.4 (0.1-3.0) 19 0.3 (0.05-1.0) 46 0.016
LH30 (IU/L)b 7.2 (3.0-45.0) 19 3.8 (0.6-24.0) 47 0.000
FSH0 (IU/L)b 2.9 (0.9-8.4) 19 2.85 (0.6-17.3) 46 0.891
FSH30 (IU/L)b 9.3 (2.3-27.7) 19 18.9 (0.8-77.9) 47 0.001
Basal LH/FSH ratiob 0.2 (0.02-0.71) 19 0.1 (0.02-1.25) 46 0.031
Peak LH/FSH ratiob 0.7 (0.26-2.67) 19 0.2 (0.05-1.25) 47 0.000
Results are presented as mean values with 95 % confidence intervals
aIndicates non-parametric tests where results are presented as median values and ranges. bIndicates parametric test with ln-tranformed data where results are
presented as the untransformed median values and ranges
Age group (years)























Fig. 2 Number of girls with precocious puberty (PP) and premature thelarche (PT) in the age groups ½-7 years
Sømod et al. International Journal of Pediatric Endocrinology  (2016) 2016:4 Page 4 of 8
age of 7 years is increasing. We excluded girls below
6 months of age because precocious puberty in this age
group is extremely rare i.e. in a study of 302 girls with
thelarche at birth or during the first 6 months of life,
none of them developed precocious puberty [12]. Girls
older than 7 years were also excluded because of the
trend towards onset of pubertal development in this age
group (”nonprogressive precocious puberty”) as a part of
the normal puberty [21]. The continuous increase in
girls referred for premature thelarche has also been ob-
served in France as published at a major international
congress on pediatric endocrinology [22]. The increasing
number of referrals in our study indicates a higher inci-
dence of PT and may have several explanations such as
changes in the ethnic composition, increasing BMI and
increased number of referrals for premature thelarche
PP+PT LH30
Age (years)
















Fig. 3 Gonadotropin releasing hormone stimulated luteinizing hormone (LH) in girls with precocious puberty (PP) and premature thelarche (PT)
in the age groups ½-7 years
PP+PT FSH30
Age (years)

















Fig. 4 Gonadotropin releasing hormone stimulated follicle stimulating hormone (FSH) in girls with precocious puberty (PP) and premature
thelarche (PT) in the age groups ½-7 years
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because of greater awareness of the condition in the
general population and by the general practitioners.
Differentiating premature thelarche from early stages
of precocious puberty in girls is difficult. Therefore, for
improving future clinical care of girls with premature
thelarche and precocious puberty, we constructed a
database on clinical and biochemical data of the girls in
our study cohort. Our aim was to identify signs, which
can help differentiate girls with premature thelarche
from girls with early stages of precocious puberty, but
also to draw attention to the challenges in using conven-
tional variables for PP diagnostics in distinguishing PT
and PP in the age group ½-7 years.
The most interesting and clinical useful discovery in
our study was, that we observed decreased SHBG levels
in girls with precocious puberty and observed no overlap
of SHBG concentrations in the two groups. Circulating
levels of SHBG and androgens correlate inversely and
SHBG usually plateau until puberty where after a decline
is recorded [23]. We did not routinely measure androgens
in our cohort but speculate that a puberty-associated in-
crease of androgen levels caused a decrease of systemic
SHBG in girls with precocious puberty. 25 % of the PP
girls who underwent a SHBG analysis had pubic hair
Tanner stage 2.
Several other parameters also differed between the
groups: Chronological age, BMI SDS, ethnic origin, bone
age advancement, basal and stimulated LH, stimulated
FSH, basal and stimulated LH/FSH ratio.
Fourteen percent of the girls, who were referred be-
cause of breast development, progressed to precocious
puberty, but the risk was strongly dependent on the age
as only 3 % of girls between 6 months and 3 years, and
41 % girls older than 3 years of age developed preco-
cious puberty. This supports the notion that breast de-
velopment in the first few years of life is most often a
physiological condition that stabilizes or regresses spon-
taneously [11, 14, 24–26] and why clinical follow-up
without hormonal examinations may be the primary op-
tion in most cases in the youngest age group. Our data
are in line with two earlier reports, where 13 and 14 %
of girls with premature thelarche, respectively, developed
precocious puberty [13, 14], but contrasts another study,
that reported a larger proportion of girls e.g. 6.1 % out
of 148 aged 6 months to 3 years progressed from prema-
ture thelarche to precocious puberty [12].
Non-European origin was associated with increased
risk for precocious puberty in our study, which supports
previous reports on the positive association between pre-
cocious puberty and ethnic origin [27, 28].
Advanced bone age is a hallmark of precocious pu-
berty [9] and was quite increased in our group of girls
with precocious puberty as compared with the girls with
premature thelarche.
According to Bizzarri et al. [12] the combined meas-
urement of basal LH and longitudinal diameter of the
uterus represents a reliable screening approach to iden-
tify subjects who should undergo GnRH testing. Our
data set revealed that only a small proportion of our study
cohort had an ultrasonography examination and the data
quality was low, and ultrasound data were therefore not
included in our study.
PP+PT Peak LH/FSH ratio
Age (years)





















Fig. 5 Gonadotropin releasing hormone stimulated LH/FSH ratio in the age groups ½-7 years
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The gold standard confirmatory laboratory test for
central idiopathic precocious puberty for girls older than
6 years of age is a GnRH stimulated LH response in the
pubertal range [29], but, so far, no reference interval
exists for girls below 6 years of age. When comparing
the group of girls progressing to precocious puberty
with the group of girls with premature thelarche, we
observed an increased basal and stimulated LH re-
sponse and an increased basal and stimulated LH/FSH
ratio. Neely et al. reported that basal LH concentrations
were above 0.3 IU/L in all girls in late puberty [30].
This was indeed in line with 89.5 % of the girls in our
cohort with precocious puberty, but 69.6 % of the girls
with premature thelarche also exhibited increased LH
concentrations leaving basal LH measurements inadequate
to identify girls with premature thelarche. Bizzarri et al. re-
ported that a basal LH concentration above 0.2 IU/L was
the best positive and negative predictor of premature the-
larche progressing into precocious puberty in 0 to 3 year
old girls [12], but contrasts the basal LH concentrations in
our study, where girls in that age group with premature
thelarche presented with a median basal LH concentration
of 0.3 IU/L. Only 57.9 % of our girls with precocious pu-
berty had a stimulated LH above 5.0 IU/L, and girls with
premature thelarche in age group ½-3 years exhibited a
stimulated LH comparable to the stimulated LH in the
precocious puberty group in 5–7 year old girls. A GnRH-
stimulated LH/FSH ratio ≥1 has been considered to have
high sensitivity and specificity for differentiating between
precocious puberty and premature thelarche [31]. How-
ever, applying a stimulated LH/FSH ratio ≥1 as a cut-off
value could not discriminate all our girls with precocious
puberty from girls with premature thelarche, which was
also observed in a recent study [12].
Surprisingly, we did not observe changes in estradiol,
inhibin B, and TSH levels in girls with precocious pu-
berty, and speculate that the lack of significance is at-
tributed to a limited data set and a large inter-individual
variability. E.g. the girl with the highest estradiol and in-
creased LH response to the GnRH test, who was assigned
to the premature thelarche group, underwent an extensive
diagnostic program and an appropriate observation period
and proved not to have precocious puberty, but rather
premature thelarche, unsustained precocious puberty [32]
or prolonged minipuberty. Usually minipuberty is consid-
ered to affect girls up 6 months of age but may last for a
prolonged period [33].
The retrospective study design is a limitation and im-
plies that data are not homogenous for the enrolled girls
causing some missing information. The missing data on
some of the girls, especially in the group with premature
thelarche, also made comparison of the studied parame-
ters difficult and indicates a selection bias for perform-
ing for example GnRH testing, bone age examination,
and pelvic ultrasonography. Furthermore, only girls born
before 2006 had a 7-year follow up, resulting in an
underestimated incidence in the years 2006 to 2012.
The assay for LH, FSH, SHBG and TSH changed from
chemiluminescence immunoassay to electrochemilumi-
nescence immunoassay during the study period, how-
ever reference values did not change for our age-group.
Conclusion
We observed that the incidence of referral for premature
thelarche is increasing in the Central Region of Denmark.
It remains to be investigated if this earlier breast develop-
ment over time will advance the entire sexual maturation.
The incidence for premature thelarche in our study may
serve as reference for future studies investigating secular
trends of clinical signs of early pubertal development.
SHBG concentrations appeared to be useful to differen-
tiate girl with premature thelarche from girls with preco-
cious puberty. The sensitivity and specificity of SHBG in
differentiating PT from PP needs to be further tested in
future prospective studies. No other isolated clinical char-
acteristic or hormonal parameter predicted the progres-
sion of premature thelarche to precocious puberty in girls
below 7 years of age. Age, BMISDS, ethnicity, bone age,
stimulated and basal LH/FSH ratio are all useful variables
for differentiating PP from PT, but with considerable over-
lap between the PT and the PP group. It is notable that
the stimulated LH value in 1–3 years old girls with PT
may be as high as in 5–7 years old girls with PP. There-
fore, in clinical practice, hormonal and x-ray testing in the
younger girls should be limited to those with atypical or
clearly progressive findings during follow-up. The GnRH
test may, in future studies, also be useful to differentiate
between premature thelarche and precocious puberty in
girls below 6 years of age, but requires establishing of a
reference interval in this age group.
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